The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is a National Cancer Institute-designated comprehensive cancer center and one of the top cancer treatment and research centers in the country. As part of the University of Maryland Medical Center, we offer innovative approaches to diagnosing and treating all types of cancer, conduct cutting-edge research to bring the latest advances in cancer treatment directly to our patients, and provide cancer screening and patient education services.

QUICK NUMBERS

- 49,262 Outpatient Visits
- 1,799 Inpatient Admissions
- 3,386 New Patients Annually
- 185 Clinical Trials
- 257 Physicians and Researchers
- $61.7M Research Funding

CANCER TREATMENT SPECIALTIES

- Blood and Marrow Transplant
- Bone and Soft Tissue Cancer
- Brain Cancer
- Breast Evaluation and Treatment
- Endocrine Malignancies

UMGCCC.ORG

A team approach to care in which specialists from all cancer disciplines work together to develop an individualized treatment plan for each patient.

Minimally invasive treatment options, including stereotactic body radiation therapy, robot-assisted surgery and the newest, targeted drug therapies.

Innovative clinical trials offering patients promising new therapies, often years before they are available commercially.

Patient-focused treatment environment featuring private rooms for all inpatients, the Stoler Pavilion for outpatient care and a dedicated pharmacy and infusion center.

An active translational research program, with experts leading major advances in cancer research, including development of cancer vaccines, new technologies, novel cancer-fighting agents and promising combination therapies.

Top-rated nursing staff specially trained in cancer care and consistently rated as outstanding in patient satisfaction surveys.

Support services, including social work, patient navigators, genetic and nutrition counseling, image renewal center and acupuncture for cancer symptom management.

Education, outreach and free cancer screenings for underserved citizens through the Baltimore City Cancer Program.

The University of Maryland Cancer Network allows Maryland residents to benefit from specialized cancer expertise and clinical trials close to home.
OUR NATIONAL PROFILE

UMGCC is a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center, a distinction shared by fewer than 50 centers across the U.S.

UMGCC is ranked among the top cancer programs in the country, according to U.S. News & World Report’s Best Hospitals list.

Cancer research funding at UMGCCC has grown dramatically since 2002—from $19.4 to $61.7 million—and continues to drive scientific discovery by our cancer experts, all of whom are on the faculty of the University of Maryland School of Medicine.

UMGCC is a leader in addressing cancer disparities, with research focused on improving access to care and treatment outcomes for minorities, who represent 30 percent of the patients in our clinical trials, compared to 2 percent nationally.

The Maryland Proton Treatment Center, which opened this year in the University of Maryland BioPark, is a next-generation radiation treatment facility expected to treat 2,000 cancer patients per year when fully operational.

A compound discovered by Dr. Angela Brodie and Dr. Vincent Njar is showing promise in clinical trials for treatment of the most advanced stage of prostate cancer. The drug, called galeterone, was “fast tracked” by the FDA to expedite its development and review to help bring it to market as quickly as possible.

Dr. Stuart Martin discovered that “microtentacles” on breast cancer cells play a key role in how cancers spread in the body.

Dr. Angela Brodie discovered aromatase inhibitors for the treatment of breast cancer. Recent trials also showed that these drugs can prevent two thirds of cancers in women at high risk for developing the disease.

Dr. Kevin Cullen’s research demonstrated for the first time that racial survival disparities in head and neck cancer are largely explained by previously unknown differences between racial and ethnic groups in the rate of human papillomavirus (HPV) infection.

UMGCC researchers are pioneering stem cell and HIV/AIDS-related cancer studies in partnership with the University of Maryland Center for Stem Cell Biology and Regenerative Medicine and the Institute of Human Virology.

Dr. Stuart Martin’s discovery of microtentacles (pictured left) on circulating tumor cells may help scientists develop ways to prevent metastasis. Here, two breast cancer cells attach to each other. The cell on the left expresses a green fluorescent protein (GFP) that makes it possible to see how its microtentacles encircle the red adjacent cell.

Updated 5/16, based on FY 2015 numbers. Numbers change throughout the year.